Sentiment Trading

Recursion Pharmaceuticals Inc. reported Q1 2025 earnings, beating estimates, but faced increased losses amid restructuring efforts, while advancing its strategic focus on oncology and rare diseases.

Recursion Pharmaceuticals reports promising results from its clinical trial of REC-4881, a potential treatment for Familial Adenomatous Polyposis (FAP), showing a 43% median reduction in polyp burden at Week 13.